EMD Millipore (www.emdmillipore. com), the Life Science division of Merck, Germany (www.merckgroup. com), announced a new initiative with Sistemic, UK (www.sistemic.co.uk), a provider of miRNA-based problemsolving services and kit-based products. The two companies are jointly developing a proprietary monitoring methodology utilizing Sistemic's miRNA marker detection capability to enable consistent growth of stem cells in EMD Millipore's Mobius ® CellReady platform. These markers could also be incorporated into a commercially available kit for quality control of stem cells in culture.
Partnership agreement: GE Healthcare & CDI GE Healthcare Life Sciences, UK (www. gelifesciences.com), has licensed Cellular Dynamics International, WI, USA (www. cellulardynamics.com), to develop, manufacture and sell cellular assays and models derived from human induced pluripotent stem (iPS) cells for use in drug discovery and toxicity screening. The agreement follows the recent announcement that GE Healthcare has expanded its license with Geron, CA, USA (www.geron.com), to obtain exclusive global rights to Geron's intellectual property and know-how for the development and sale of cellular assays derived from iPS cells. Financial terms were not disclosed. HumanZyme, IL, USA (www.humanzyme. com), and PacificGMP, CA, USA (www. pacificgmp.com), entered into a partnership to manufacture clinical-grade human growth factors and cytokines. The goal is to provide a source of these proteins to regenerative medicine developers to differentiate stem cells into cell types that will be used to treat various diseases or injuries. HumanZyme brings its HumanKine ® growth factor and cytokine product line to the partnership with PacificGMP, which has experience in manufacturing GMP-certified recombinant human proteins intended for human clinical use. 
Healthpoint
Healthpoint Biotherapeutics, TX, USA (www.healthpointbio.com), introduced a 5 × 7 cm size of OASIS ® Ultra Tri-Layer Matrix, a naturally derived extracellular matrix material formed from three layers of porcine small intestinal submucosa designed to provide increased structure for difficult-to-heal and chronic wounds.
Irvine Scientific
Irvine Scientific, CA, USA (www. irvinesci.com), launched the cell therapy PRIME-XV™ product portfolio as part of the company's commitment to accelerate basic research and clinical applications in cell therapy and regenerative medicine. PRIME-XV products include: a recombinant human matrix protein MatrIS F, intended for the culture of human stem/progenitor cells under serum-free conditions; mesenchymal stem cell (MSC) serum-free medium, [2] . Additional information about the RANGER clinical trial can be found at www.clinicaltrials.gov (ID: NCT01526681).
Cytori
Cytori Therapeutics, CA, USA (www.cytori. com), announced publication of a peerreviewed case series using Cytori's Celution ® system [3] . Three patients suffering from long-standing complex cryptogland ular fistula in ano were treated using fat grafts enriched with their own adipose-derived stem and regenerative cells, processed using Cytori's Celution system. The stem cell-enriched graft was injected directly into the tissue surrounding the fistula to close the fistula track. The interior opening of the fistula was closed with a mucosal advancement flap. All three patients remain fully healed at 2-3-year follow-up, with one patient undergoing colostomy reversal to restore bowel continuity.
VistaGen
VistaGen Therapeutics, CA, USA (www. vistagen.com), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, announced a significant advance in its development of LiverSafe 3D™, a human liver cellbased bioassay system designed to predict liver toxicity and drug metabolism issues in connection with the company's drug rescue activities. VistaGen's LiverSafe 3D, together with optimized culture protocols and without the need for any purification, is now capable of producing differentiated populations of cells containing greater than 70% albumin-positive human hepatocytes, and greater than 40% of these hepatocytes express the mature CYP3A4 drug-metabolizing enzyme. CYP3A4 is a crucial enzyme in adult liver functions and widely viewed as an important functional marker for adult stem cell-derived hepatocytes. This enzyme is responsible for metabolizing over 50% of the drugs approved by the US FDA. After purification, nearly 90% of LiverSafe 3D hepatocytes expressed the CYP3A4 enzyme. Advanced Cell Technology Advanced Cell Technology, MA, USA (www.advancedcell.com), completed the second patient cohort in the company's US and European clinical trials for Stargardt's macular dystrophy and agerelated macular degeneration using hES cell-derived retinal pigment epithelial cells. The patients were injected with 100,000 cells, as compared with 50,000 cells in the first cohort. The outpatient transplantation surgeries were performed successfully and the patients are recovering uneventfully. Further information about the company's clinical trials for macular dystrophy is available at www. clinicaltrials.gov (ID: NCT01469832, NCT01345006 and NCT01344993). The company is eagerly anticipating proceeding to the third, 150,000-cell patient cohort. Avita Avita Medical, UK (www.avitamedical. com), has initiated a multicenter randomized control study on the use of ReCell ® Spray-On Skin ® in the treatment of venous leg ulcers. Up to five European centers from countries including the UK, Germany, France and Denmark will participate in the study. The study will enroll 65 participants. The control group will receive standard care (debridement, cleansing) and Profore ® multilayer compression therapy (replacing the wound contact layer with Telfa™ Clear). The ReCell group will receive ReCell in addition to care received by the control group as described. Additional information about the clinical trial can be found at www.clinicaltrials.gov (ID: NCT01743053).
future science group
News & Views -Industry Update Fate Therapeutics Fate Therapeutics, CA, USA (www. fatetherapeutics.com), initiated a randomized, controlled, Phase II multicenter study of its investigational hematopoietic stem cell therapy, ProHema™, in adult patients undergoing double umbilical cord blood transplantation for hematologic malign ancy. ProHema is produced through a proprietary, 2-h, ex vivo modulation process, which has been shown to signif icantly activate key biological pathways involved in hematopoietic stem cell homing, proliferation and survival in preclinical models. The Phase II study is expected to enroll at least 45 adult patients. Patients will be randomized, with a ratio of 2:1, to receive either ProHema plus an unmanipulated cord blood unit or two unmanipulated cord blood units. The study will evaluate time to neutrophil and platelet recovery, incidence of serious infections and graft-versus-host disease, 100-day mortality and relative dominance of ProHema over the unmanipulated cord in contributing to reconstitution. The Belgian biotechnology company, Cardio3 BioSciences (C3BS; Belgium) (www.c3bs.com), has received authorization from the Belgian Federal Agency for Medicines and Health Products (www. fagg-afmps.be/en) to begin its Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium. This represents a world premiere for a regenerative medicine product targeting heart failure to be tested in the context of a Phase III trial. This Phase III trial builds on the successful outcome of the Phase II trial conducted between 2009 and 2010 in multiple clinical sites in Belgium, Serbia and Switzerland. C3BS-CQR-1 consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle cells that behave identically to those lost to heart disease. Cardio3 BioSciences has also developed C-Cathez ® , an injection catheter for delivery of biotherapeutic agents into the myocardium. NTCELL will be codeveloped with Otsuka Pharmaceutical Factory, Japan (www.otsukakj.jp/en), for the treatment of Parkinson's disease and other neurological disorders. LCT will receive an upfront payment of US$3.11 million (AU$3 million) within 30 days of signing. In addition, Otsuka will fund all development costs, estimated at US$2.08 million (AU$2 million), to complete the previously announced Phase I trial of NTCELL in Parkinson's disease. LCT will receive a further milestone payment of US$2.08 million (AU$2 million) when the first patient in the Phase I Parkinson's trial has been safely implanted with NTCELL. This is expected to occur in the second quarter of 2013. In return, LCT has granted Otsuka an exclusive option to jointly develop and commercialize NTCELL in Parkinson's and other neurological diseases, including hearing loss, through Diatranz Otsuka, the 50:50 joint venture formed between LCT and Otsuka.
Mesoblast
Mesoblast, Australia (www.mesoblast. com), has reached agreement with the FDA on the manufacturing process to supply its proprietary mesenchymal precursor cells for Phase III clinical trials. In addition, it has established with the FDA a clear pathway for commercial manufacturing supply of its cell therapy products. [4] and for which a North American Phase III trial was initiated in September 2012. BioTime BioTime, CA, USA (www.biotimeinc. com), and its recently formed subsidiary BioTime Acquisition Corporation (BAC) have jointly entered into a nonbinding letter of intent (LOI) for a US$10 million investment from a private investor to provide financing for the recently announced proposed acquisition of Geron's stem cell assets by BAC. Under the terms outlined in the LOI, the investor will invest US$5 million in BioTime by purchasing 1.35 million BioTime common shares at a purchase price of approximately US$3.70 per share, and warrants to purchase 650,000 additional BioTime common shares with an exercise price of US$5 per share and a 3-year term. In addition, the investor will contribute US$5 million in cash to BAC in exchange for shares of BAC common stock that, upon issuance, will represent approximately 7% of the BAC common stock then issued and outstanding, plus warrants to purchase approximately 350,000 additional shares of BAC common stock at an exercise price of US$5 per share, with a 3-year term.
Regulations, Approvals & Acquisitions
In related news, BioTime and BAC have jointly entered into a nonbinding LOI with Geron Corporation, CA, USA (www.geron.com). The LOI contains broad terms of a potential transaction through which Geron would contribute to BAC its intellectual property and other assets related to Geron's discontinued hES cell programs. BioTime would contribute US$5 million in cash, US$30 million of BioTime common shares, warrants to purchase 8 million common shares of BioTime at a prespecified price, rights to use certain hES cell lines and minority stakes in two of BioTime's subsidiaries to BAC. In addition, a private investor would invest US$5 million in cash in BAC. Following consummation of the potential transaction, Geron stockholders would receive shares representing 21.4% of the common stock of BAC, as well as warrants to purchase 8 million shares of BioTime common stock at a prespecified price. BioTime would own approximately 71.6%, and a private investor would own approximately 7.0% of the outstanding BAC common stock for their US$5 million investment. BioTime would also receive warrants that would enable it to increase its ownership in BAC by approximately 2%, which would reduce the Geron stockholders' ownership in BAC to 19.2%. BAC would also be committed to pay royalties to Geron on the sale of products that are commercialized in reliance upon Geron patents acquired by BAC. The LOI is not a binding agreement to complete the transaction. Consummation of the transaction is necessarily subject to entering into a definitive agreement between the parties containing terms and conditions yet to be negotiated. Cytori Cytori, CA, USA (www.cytori.com), announced the sale of 7,020,000 shares of its common stock in an underwritten public offering at a price of US$2.85 per share to the public. The net offering proceeds to Cytori from the sale of the shares are expected to be approx imat ely US$18.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses, but excluding any exercise of the underwriters' overallotment option. Cytori anticipates using the net proceeds from this offering for general corporate purposes, including the continued development, manufacture, marketing and sale of its Celution System family of products, including related research and clinical trials, and other related research and development, sales and marketing, and general administrative expenses, working capital, capital expenditures and future acquisitions.
Kiadis Kiadis Pharma, The Netherlands (http:// kiadis.com), has raised US$13.22 million (€10 million) in an equity financing round. The financing will enable Kiadis Pharma to perform a confirmatory multicenter Phase II proof-of-concept study with its lead product ATIR™, and to prepare a pivotal Phase II/III study. ATIR is administered as an adjunctive treatment on top of a haploidentical stem cell transplantation, with the goal of enhanc ing early immune reconstitution without causing graft-versus-host disease. 
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